(NASDAQ: ACIU) Ac Immune Sa's forecast annual revenue growth rate of 47.35% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Ac Immune Sa's revenue in 2025 is $30,343,333.On average, 3 Wall Street analysts forecast ACIU's revenue for 2025 to be $3,666,585,327, with the lowest ACIU revenue forecast at $456,867,215, and the highest ACIU revenue forecast at $10,041,037,700. On average, 2 Wall Street analysts forecast ACIU's revenue for 2026 to be $2,457,041,925, with the lowest ACIU revenue forecast at $1,731,074,899, and the highest ACIU revenue forecast at $3,183,008,951.
In 2027, ACIU is forecast to generate $11,569,283,638 in revenue, with the lowest revenue forecast at $11,195,757,036 and the highest revenue forecast at $11,942,810,240.